Holen Sie sich die Stockscreener-App
2.51
1.57%
-0.04
Schlusskurs vom Vortag:
$2.55
Offen:
$2.53
24-Stunden-Volumen:
4,032
Relative Volume:
0.01
Marktkapitalisierung:
$11.12M
Einnahmen:
$20,000
Nettoeinkommen (Verlust:
$-11.06M
KGV:
-0.8823
EPS:
-2.8449
Netto-Cashflow:
$-10.53M
1W Leistung:
-4.56%
1M Leistung:
-4.56%
6M Leistung:
+16.74%
1J Leistung:
-16.61%
1-Tages-Spanne:
$2.50
$2.56
1-Wochen-Bereich:
$2.50
$2.652
52-Wochen-Spanne:
$1.7645
$3.29
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
Firmenname
Kiora Pharmaceuticals Inc
Sektor
Branche
Telefon
858-224-9600
Adresse
169 SAXONY RD., ENCINITAS
Compare KPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
2.51 | 11.12M | 20,000 | -11.06M | -10.53M | -2.8449 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kiora Pharmaceuticals Inc Aktie (KPRX) Neueste Nachrichten
Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. – LS:A40EG5 - TradingView
Kiora Pharmaceuticals Inc. (KPRX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. – GETTEX:7EY - TradingView
Price to book forward of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX - TradingView
KPRXKiora Pharmaceuticals Inc Latest SEC Filings - Finviz
Form 4 Kiora Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com India
Kiora (NASDAQ: KPRX) CFO uses 911 shares to cover tax obligations - Stock Titan
[Form 4] KIORA PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Kiora Pharmaceuticals (KPRX) Holds Steady Near Support as Biotech Sector WatchesRelative Volume - dars.gov.et
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium - Yahoo Finance
Kiora set for Piper Sandler fireside chat on July 9 - Stock Titan
Kiora Pharmaceuticals Inc Warrant 2022-27.09.27 on Kiora Pharma A Financial Disclosures & SEC Filings - TradingView
Kiora Pharmaceuticals (KPRX) Slides Marginally as Biotech Sector Remains CautiousStock Analysis - dars.gov.et
Kiora Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:KPRX) - TradingView
KPRX Forecast — Price Target — Prediction for 2027 - TradingView
7EY Forecast — Price Target — Prediction for 2027 - TradingView
Why Did KPRX Stock Surge 17% Pre-Market Today? - Stocktwits
Kiora Pharmaceuticals Inc (KPRX) Institutional Confidence - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Analysts Are Bullish on Top Healthcare Stocks: Ascentage Pharma Group International (HK:6855), Kiora Pharmaceuticals (KPRX) - The Globe and Mail
KPRX SEC FilingsKIORA PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Kiora Pharmaceuticals (KPRX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Kiora Pharmaceuticals’ KIO-300 Shows Significant Seizure Suppression in Preclinical Epilepsy Model, Revealing Potential Beyond Ophthalmology 1 – Minichart - Minichart
Kiora Pharmaceuticals Inc (KPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model - TMX Newsfile
Kiora Pharmaceuticals (NASDAQ: KPRX) reports KIO-300 epilepsy model data - Stock Titan
Kiora Pharmaceuticals Inc (KPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Kiora's KIO-300 cut epileptiform activity in epilepsy model - Stock Titan
Kiora Pharmaceuticals Inc (KPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kiora Pharmaceuticals (NASDAQ: KPRX) director receives stock options for 25,000 shares - Stock Titan
Kiora Pharmaceuticals (KPRX) director receives 25,000 stock options grant - Stock Titan
Director at Kiora (KPRX) receives 25,000 stock options at $2.63 strike - Stock Titan
Kiora Pharmaceuticals (KPRX) director granted 25,000 stock options at $2.63 strike - Stock Titan
Kiora Pharmaceuticals (KPRX) director awarded 25,000 stock options - Stock Titan
Kiora (KPRX) director Praveen Tyle receives stock options for 40,000 shares - Stock Titan
Kiora Pharmaceuticals Shareholders Approve Expanded Equity Incentive Plan - TipRanks
Kiora Pharmaceuticals (NASDAQ: KPRX) OKs 1.5M-share equity plan boost and re-elects directors - Stock Titan
Kiora Pharmaceuticals (KPRX) Slips 4.9% as Stock Tests Key Support LevelsAD Line Divergence - newsline.com
Kiora Pharmaceuticals (KPRX) registers 11.8M shares including warrants - Stock Titan
Kiora Pharmaceuticals (KPRX) Holds Steady Near Support as Biotech Sector Faces HeadwindsTrading Ideas - The Legal Advocate
[EFFECT] KIORA PHARMACEUTICALS INC SEC Filing - Stock Titan
Kiora Pharmaceuticals (KPRX) Rallies 5.5%: Key Levels to Watch After Recent UptickIV Spike - dars.gov.et
Kiora Pharmaceuticals (KPRX) Slips 4.5% as Stock Tests Key Support LevelDealer Gamma - The Legal Advocate
Kiora Pharmaceuticals Q1 2026 Earnings: EPS Beat Masks Continued Pre-Revenue Status as Stock SlipsAnalyst Drop Coverage - Newser
Kiora Pharmaceuticals (NASDAQ: KPRX) registers 11.8M resale shares - Stock Titan
Nantahala reports 9.99% stake in Kiora Pharmaceuticals (KPRX) - Stock Titan
Alyeska files 13G for Kiora (NASDAQ: KPRX) reporting 9.99% stake - Stock Titan
Finanzdaten der Kiora Pharmaceuticals Inc-Aktie (KPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):